{'fraction_non_alphanumeric': 0.02577319587628866, 'fraction_numerical': 0.02190721649484536, 'mean_word_length': 5.421487603305785, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
In This Issue

Long non-coding RNAs and prostate cancer Page 2107–14 Prostate cancer remains one of the leading causes of cancer morbidity and mortality in developed countries, with several studies identifying long non-coding RNAs (lncRNAs) as modulators of key cellular processes in the disease. In this review, Misawa et al. summarize the current knowledge of lncRNA expression patterns and mechanisms in prostate cancer, which contribute to carcinogenesis. They specifically focus on lncRNA regulation by androgen receptor and expression in castration-resistant prostate cancer. This review highlights the potential use of lncRNAs as novel therapeutic targets, or as much-needed biomarkers with the potential to help determine therapeutic approaches. doi: 10.1111/cas.13352